Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review describes various T-cell-mediated alopecias characterized by distinct lymphocytic patterns and explores their pathophysiology. It highlights the role of CD8+ and regulatory T cells, the JAK/STAT pathway, and stem cell niches, contributing to understanding and potentially addressing these hair loss conditions.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This study constructed a consensus single-cell atlas for hidradenitis suppurativa tunnels, identifying distinct fibro-inflammatory microenvironments with potential drug targets, suggesting TNF blockade alone may not be effective for all lesion types.

This study's new single-cell atlas of hidradenitis suppurativa tunnels identifies distinct fibro-inflammatory microenvironments, suggesting that TNF blockade may not address the primary pathway in many lesions.

This study created a comprehensive single-cell atlas of hidradenitis suppurativa tunnels, identifying distinct microenvironmental endotypes linked to specific signaling pathways, suggesting that TNF blockade may not effectively address predominant pathways in many lesions and highlighting the potential for individualized treatment strategies.

This study constructed a consensus single-cell atlas of hidradenitis suppurativa tunnels, identifying distinct microenvironmental endotypes with different inflammatory and fibrotic profiles, suggesting that TNF blockade may not be sufficient for addressing all lesions.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

This study documented a case where the medication baricitinib effectively promoted hair regrowth in a woman with alopecia areata but also led to an unexpected side effect of hypertrichosis, suggesting a need to further explore the JAK/STAT pathway's role in hair growth dynamics.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

This review discusses how urban air pollutants may influence the regulation of JAK3 signaling in alopecia areata and reports no new experimental results; the authors integrate existing data to map potential pathways and biomarkers.

This study found that cell-free RNA, particularly DNAJB9, shows potential as a biomarker for diagnosing and prognosing female androgenetic alopecia using a machine learning model.

This study examines the genetic underpinnings of chronic dermatological conditions like acne, androgenetic alopecia, and alopecia areata, concluding that a deep understanding of these mechanisms can advance patient-specific treatments and inform cosmetic practices related to skin and hair health.

This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.

This study observed distinct plasma miRNA profiles in alopecia areata, identifying several miRNAs downregulated in both mild and severe forms; machine learning models demonstrated strong predictive accuracy, and kinase inhibitors were suggested as promising therapeutic targets based on pathway analysis.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This review discusses the mechanisms underlying the collapse of hair follicle immune privilege in alopecia areata and emphasizes the importance of therapeutic strategies aimed at restoring immune tolerance.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

This review discusses central centrifugal cicatricial alopecia in adult women of African descent and reports no clinical results; the authors highlight traditional treatments and their impact on quality of life.

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

This study found that in a human skin organ culture model of pemphigus vulgaris, split formation led to significant upregulation of IFNγ and TNFα-related genes, indicating secondary effects from mechanical stress, not direct changes from autoantibodies.